Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
A case that explores the impact of financial incentives from insurance companies on the patient-physician relationship and whether or not they should be disclosed to a patient.
When patients and physicians disagree on the use of genetic engineering technology, physicians must act in accordance with professional ethics and society's guidelines.
Genetic information is redefining what society and the medical profession considers to be normal and what departures from the norm are deserving of medical intervention.
Physicians need to understand when it may be appropriate to let patients get involved in medical decision-making and when it may be necessary to provide their personal medical judgment.
Medical ethicists have discussed the use of race classification in determining disease prevalence and the response of specific ethnic groups to different medications.